Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Madison, WI
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Decatur, GA
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Durham, NC
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
La Jolla, CA
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated:  8/1/2016
Investigational Site Number 032001
mi
from
Capital Federal,
A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)
A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)
Status: Enrolling
Updated: 8/1/2016
Investigational Site Number 032001
mi
from
Capital Federal,
Click here to add this to my saved trials
Dose Ranging Study of OTO-201 in AOMT
A 1-Month, Prospective, Multicenter, Randomized, Dose-Ranging, Sham-Controlled, Blinded Study of OTO-201 Given as a Single Administration for Treatment of Acute Otitis Media With Tympanostomy Tubes in Pediatric Subjects
Status: Enrolling
Updated:  8/1/2016
Contact Otonomy call center for trial locations
mi
from
San Diego, CA
Dose Ranging Study of OTO-201 in AOMT
A 1-Month, Prospective, Multicenter, Randomized, Dose-Ranging, Sham-Controlled, Blinded Study of OTO-201 Given as a Single Administration for Treatment of Acute Otitis Media With Tympanostomy Tubes in Pediatric Subjects
Status: Enrolling
Updated: 8/1/2016
Contact Otonomy call center for trial locations
mi
from
San Diego, CA
Click here to add this to my saved trials
4R for Guideline Indicated BRCA Testing of Breast Center Patients
4R (Right Information and Right Care to the Right Patient at the Right Time) for Guideline Indicated BRCA Genetic Assessment of Breast Center Patients
Status: Enrolling
Updated:  8/2/2016
Northwestern Memorial Hospital
mi
from
Chicago, IL
4R for Guideline Indicated BRCA Testing of Breast Center Patients
4R (Right Information and Right Care to the Right Patient at the Right Time) for Guideline Indicated BRCA Genetic Assessment of Breast Center Patients
Status: Enrolling
Updated: 8/2/2016
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Children's Hospital Colorado
mi
from
Aurora, CO
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Emory Children's Healthcare of Atlanta
mi
from
Atlanta, GA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Emory Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Johns Hopkins University
mi
from
Baltimore, MD
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated:  8/2/2016
The Hospital for Sick Kids
mi
from
Toronto,
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Enrolling
Updated: 8/2/2016
The Hospital for Sick Kids
mi
from
Toronto,
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Valhalla, NY
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Valhalla, NY
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated:  8/4/2016
mi
from
Melbourne,
A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE AND 4) ASSESSING PK AND SAFETY OF NEW OPTIMIZED FORMULATION OF RO5503781 WITH CYTARABINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
Status: Enrolling
Updated: 8/4/2016
mi
from
Melbourne,
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
John Theurer Cancer Center
mi
from
Hackensack, NJ
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated:  8/8/2016
Local Institution
mi
from
San Miguel De Tucuman,
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).
Status: Enrolling
Updated: 8/8/2016
Local Institution
mi
from
San Miguel De Tucuman,
Click here to add this to my saved trials
Stopping Cavities Study: Diammine Silver Fluoride
Pragmatic Trial of Topical Diammine Silver Fluoride for Dental Caries Arrest
Status: Enrolling
Updated:  8/8/2016
Advantage Dental Plans
mi
from
Redmond, OR
Stopping Cavities Study: Diammine Silver Fluoride
Pragmatic Trial of Topical Diammine Silver Fluoride for Dental Caries Arrest
Status: Enrolling
Updated: 8/8/2016
Advantage Dental Plans
mi
from
Redmond, OR
Click here to add this to my saved trials
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated:  8/11/2016
Shionogi Research Site
mi
from
Jackson, MS
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated: 8/11/2016
Shionogi Research Site
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated:  8/11/2016
Shionogi Research Site
mi
from
Lima, OH
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated: 8/11/2016
Shionogi Research Site
mi
from
Lima, OH
Click here to add this to my saved trials
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated:  8/11/2016
Shionogi Research Site
mi
from
Pleven,
A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin
Status: Enrolling
Updated: 8/11/2016
Shionogi Research Site
mi
from
Pleven,
Click here to add this to my saved trials
Intravenous Exenatide (Byetta) During Surgery
Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial
Status: Enrolling
Updated:  8/17/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Intravenous Exenatide (Byetta) During Surgery
Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial
Status: Enrolling
Updated: 8/17/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)
Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis to Determine Choice Between Antibiotics Alone vs. Appendectomy
Status: Enrolling
Updated:  8/18/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)
Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis to Determine Choice Between Antibiotics Alone vs. Appendectomy
Status: Enrolling
Updated: 8/18/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated:  11/4/2016
University of Alabama
mi
from
Birmingham, AL
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated: 11/4/2016
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated:  11/4/2016
University of South Florida
mi
from
Tampa, FL
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated: 11/4/2016
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated:  11/4/2016
Rush University Medical Center
mi
from
Chicago, IL
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated: 11/4/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated:  11/4/2016
Duke University
mi
from
Durham, NC
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated: 11/4/2016
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated:  11/4/2016
Oregon Health and Sciences University
mi
from
Portland, OR
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status: Enrolling
Updated: 11/4/2016
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Intensive Dysarthria Sessions in Adults and Children With Down Syndrome
Intensive Dysarthria Sessions in Adults and Children With Down Syndrome
Status: Enrolling
Updated:  11/22/2016
Duke University Health System
mi
from
Durham, NC
Intensive Dysarthria Sessions in Adults and Children With Down Syndrome
Intensive Dysarthria Sessions in Adults and Children With Down Syndrome
Status: Enrolling
Updated: 11/22/2016
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
Exercise and Quality of Life in Leukemia Patients
Effects of Exercise on Patient Reported Outcomes in Newly Diagnosed Adults With Acute Leukemia During Induction Treatment: Exercise and Quality of Life in Leukemia Patients (EQUAL)
Status: Enrolling
Updated:  11/22/2016
University of North Carolina Lineberger Comprehenisive Cancer Center
mi
from
Chapel Hill, NC
Exercise and Quality of Life in Leukemia Patients
Effects of Exercise on Patient Reported Outcomes in Newly Diagnosed Adults With Acute Leukemia During Induction Treatment: Exercise and Quality of Life in Leukemia Patients (EQUAL)
Status: Enrolling
Updated: 11/22/2016
University of North Carolina Lineberger Comprehenisive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Registry of Mastectomy for Breast Cancer Risk Reduction
Registry of Mastectomy for Breast Cancer Risk Reduction
Status: Enrolling
Updated:  12/1/2016
Georgetown University Hospital
mi
from
Washington,
Registry of Mastectomy for Breast Cancer Risk Reduction
Registry of Mastectomy for Breast Cancer Risk Reduction
Status: Enrolling
Updated: 12/1/2016
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients
Evaluation of Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients for Reconstructive Surgical Procedures
Status: Enrolling
Updated:  12/5/2016
Shriners Hospital for Children
mi
from
Boston, MA
Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients
Evaluation of Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients for Reconstructive Surgical Procedures
Status: Enrolling
Updated: 12/5/2016
Shriners Hospital for Children
mi
from
Boston, MA
Click here to add this to my saved trials
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Compassionate Use Arm - ABI541 Auditory Brainstem Implant for Neurofibromatosis Type 2 Patients With Deafness
Status: Enrolling
Updated:  12/5/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Compassionate Use Arm - ABI541 Auditory Brainstem Implant for Neurofibromatosis Type 2 Patients With Deafness
Status: Enrolling
Updated: 12/5/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns
Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns
Status: Enrolling
Updated:  12/5/2016
University of South Alabama Dept. of Surgery
mi
from
Mobile, AL
ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns
Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns
Status: Enrolling
Updated: 12/5/2016
University of South Alabama Dept. of Surgery
mi
from
Mobile, AL
Click here to add this to my saved trials
ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns
Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns
Status: Enrolling
Updated:  12/5/2016
Lac & Usc Medical Center
mi
from
Los Angeles, CA
ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns
Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns
Status: Enrolling
Updated: 12/5/2016
Lac & Usc Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns
Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns
Status: Enrolling
Updated:  12/5/2016
Shands Burn Center at the University of Florida
mi
from
Gainsville, FL
ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns
Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns
Status: Enrolling
Updated: 12/5/2016
Shands Burn Center at the University of Florida
mi
from
Gainsville, FL
Click here to add this to my saved trials